Study randomized locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) patients in a 1:1 ratio into placebo plus atezolizumab or tiragolumab plus atezolizumab groups. The gene discussed is CD274; the disease is non-small cell lung carcinoma.